Bruker Past Earnings Performance
Past criteria checks 2/6
Bruker has been growing earnings at an average annual rate of 16.3%, while the Life Sciences industry saw earnings growing at 15.4% annually. Revenues have been growing at an average rate of 10.2% per year. Bruker's return on equity is 16.5%, and it has net margins of 9.4%.
Key information
16.3%
Earnings growth rate
17.6%
EPS growth rate
| Life Sciences Industry Growth | 19.5% |
| Revenue growth rate | 10.2% |
| Return on equity | 16.5% |
| Net Margin | 9.4% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Bruker makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 3,241 | 305 | 855 | 356 |
| 30 Jun 24 | 3,120 | 352 | 804 | 329 |
| 31 Mar 24 | 3,001 | 402 | 762 | 308 |
| 31 Dec 23 | 2,965 | 427 | 730 | 295 |
| 30 Sep 23 | 2,818 | 319 | 687 | 275 |
| 30 Jun 23 | 2,715 | 319 | 644 | 260 |
| 31 Mar 23 | 2,621 | 312 | 625 | 248 |
| 31 Dec 22 | 2,531 | 297 | 608 | 236 |
| 30 Sep 22 | 2,506 | 275 | 598 | 231 |
| 30 Jun 22 | 2,476 | 274 | 605 | 226 |
| 31 Mar 22 | 2,458 | 282 | 577 | 223 |
| 31 Dec 21 | 2,418 | 277 | 563 | 221 |
| 30 Sep 21 | 2,362 | 270 | 544 | 220 |
| 30 Jun 21 | 2,264 | 238 | 518 | 216 |
| 31 Mar 21 | 2,118 | 204 | 485 | 204 |
| 31 Dec 20 | 1,988 | 158 | 472 | 198 |
| 30 Sep 20 | 1,960 | 158 | 470 | 188 |
| 30 Jun 20 | 1,970 | 165 | 480 | 185 |
| 31 Mar 20 | 2,035 | 177 | 503 | 190 |
| 31 Dec 19 | 2,073 | 197 | 500 | 188 |
| 30 Sep 19 | 2,026 | 207 | 491 | 186 |
| 30 Jun 19 | 1,972 | 189 | 473 | 182 |
| 31 Mar 19 | 1,925 | 184 | 459 | 177 |
| 31 Dec 18 | 1,896 | 180 | 449 | 173 |
| 30 Sep 18 | 1,873 | 98 | 443 | 172 |
| 30 Jun 18 | 1,842 | 92 | 440 | 171 |
| 31 Mar 18 | 1,813 | 84 | 432 | 167 |
| 31 Dec 17 | 1,766 | 79 | 420 | 162 |
| 30 Sep 17 | 1,706 | 151 | 407 | 157 |
| 30 Jun 17 | 1,664 | 161 | 399 | 154 |
| 31 Mar 17 | 1,621 | 152 | 396 | 151 |
| 31 Dec 16 | 1,611 | 154 | 394 | 148 |
| 30 Sep 16 | 1,619 | 146 | 393 | 148 |
| 30 Jun 16 | 1,621 | 111 | 393 | 144 |
| 31 Mar 16 | 1,646 | 119 | 390 | 145 |
| 31 Dec 15 | 1,624 | 102 | 392 | 146 |
| 30 Sep 15 | 1,654 | 66 | 408 | 151 |
| 30 Jun 15 | 1,677 | 60 | 420 | 158 |
| 31 Mar 15 | 1,739 | 55 | 436 | 165 |
| 31 Dec 14 | 1,809 | 57 | 451 | 174 |
| 30 Sep 14 | 1,853 | 66 | 451 | 182 |
| 30 Jun 14 | 1,872 | 77 | 449 | 185 |
| 31 Mar 14 | 1,870 | 83 | 441 | 187 |
| 31 Dec 13 | 1,839 | 80 | 438 | 191 |
Quality Earnings: B2RK34 has high quality earnings.
Growing Profit Margin: B2RK34's current net profit margins (9.4%) are lower than last year (11.3%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: B2RK34's earnings have grown by 16.3% per year over the past 5 years.
Accelerating Growth: B2RK34's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: B2RK34 had negative earnings growth (-4.5%) over the past year, making it difficult to compare to the Life Sciences industry average (-4.5%).
Return on Equity
High ROE: B2RK34's Return on Equity (16.5%) is considered low.